BRTX - CIK 0001505497
BioRestorative Therapies, Inc. (BRTX) reported revenue of $359.70K for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $359.70K | -10.3% |
| FY 2024 | $401.00K | +175.0% |
| FY 2023 | $145.80K | +21.7% |
| FY 2022 | $119.80K | +160.4% |
| FY 2021 | $46.00K | -40.3% |
| FY 2020 | $77.00K | -40.8% |
| FY 2019 | $130.00K | +17.1% |
| FY 2018 | $111.00K | +37.0% |
| FY 2017 |
BioRestorative Therapies, Inc. (BRTX) reported revenue of $359.70K for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, BioRestorative Therapies, Inc.'s revenue grew from $0.00 to $359.70K.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $81.00K |
| +122.8% |
| FY 2016 | $36.35K | -94.2% |
| FY 2015 | $628.91K | +51.2% |
| FY 2014 | $416.00K | +24661.7% |
| FY 2013 | $1.68K | -89.2% |
| FY 2012 | $15.59K | - |
| FY 2011 | $0.00 | - |